The interleukin (IL)-1 family member IL-1α is a ubiquitous and pivotal pro-inflammatory
cytokine. The IL-1α precursor is constitutively present in nearly all cell types in health, but is …

Objective Mepolizumab proved to be an efficacious treatment for eosinophilic granulomatosis
with polyangiitis (EGPA) at a dose of 300 mg every 4 weeks in the randomized, controlled …

This study aimed to evaluate the role of interleukin (IL)-1 inhibitors anakinra (ANA) and
canakinumab (CAN) in the treatment of Behçet’s disease (BD)-related uveitis. Multicenter …

Aims Novel therapies are needed for recurrent pericarditis, particularly when corticosteroid
dependent and colchicine resistant. Based on limited data, interleukin-1 blockade with …

A complex web of dynamic relationships between innate and adaptive immunity is now
evident for many autoinflammatory and autoimmune disorders, the first deriving from abnormal …

Growing data have provided encouraging results on the use of interleukin (IL)-1 inhibitors in
Behçet’s disease (BD). This study was aimed at reporting the largest experience with anti-IL-…

The study aim was to evaluate the efficacy of adalimumab (ADA) in a large series of Behçet’s
disease (BD)-related uveitis. We performed a multicenter retrospective observational study …

European and Asian studies report conflicting data on the risk of hepatitis B virus (HBV)
reactivation in rheumatologic patients with a previously resolved HBV (prHBV) infection …

Background: Interleukin (IL)-1 plays a crucial role in the pathogenesis of Adult onset Still’s
disease (AOSD). Objectives: To evaluate the efficacy and safety of anakinra (ANA) and …

Background: Interleukin (IL)-1 inhibitors have been suggested as possible therapeutic
options in a large number of old and new clinical entities characterized by an IL-1 driven …